firmonertinib + pemetrexed + carboplatin

Firmonertinib + pemetrexed + carboplatin is a combination regimen investigated for the first-line treatment of locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). The regimen combines firmonertinib (also known as furmonertinib), an oral, third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI) active against classical and uncommon EGFR mutations (such as exon 20 insertions and PACC mutations), with a standard chemotherapy doublet consisting of pemetrexed (an antifolate antimetabolite) and carboplatin (a platinum-based alkylating agent). This triple combination is being evaluated in a Phase 2 clinical trial sponsored by Anhui Provincial Cancer Hospital as part of an adaptive treatment strategy guided by circulating tumor DNA (ctDNA) minimal residual disease (MRD) status to optimize clinical efficacy and manage toxicity in patients with advanced EGFR-mutated NSCLC.

Other names

furmonertinib + pemetrexed + carboplatinfirmonertinib/pemetrexed/carboplatinfurmonertinib/pemetrexed/carboplatin